Chemiluminescence Immunoassay (CLIA): Principle, Procedure, and Interpretation

A serology lab that once ran an ELISA plate for hepatitis B surface antigen now gets the same result from an automated analyzer in under an hour, with a wider measuring range and no plate to wash. The method behind that shift is chemiluminescence, and understanding how it reports a result is what lets you trust the number it prints.

What a chemiluminescence immunoassay measures

A chemiluminescence immunoassay is an immunoassay that detects an antigen or antibody using a label that emits light through a chemical reaction, rather than producing a color (as in ELISA) or radioactivity (as in radioimmunoassay). The antibody-antigen binding step is the same idea used across immunoassays. What differs is the signal: the bound label triggers a chemical reaction that releases photons, and a luminometer measures the light emitted. The amount of light is proportional to the amount of analyte in the sample.

Because light emission can be measured over a very wide range and against almost no background, chemiluminescence gives the method its two defining strengths: high sensitivity and a broad dynamic range.

Why CLIA was developed: the problem it solves

Chemiluminescence immunoassay was developed to keep the sensitivity of radioimmunoassay while removing its central drawback. Radioimmunoassay is highly sensitive, but it uses radioactive labels, which require licensing, shielding, radioactive-waste disposal, and reagents with a short usable life. CLIA reaches comparable or better sensitivity using a chemiluminescent label, so it removes the radioactive hazard entirely. For that reason CLIA and related non-radioactive methods have largely replaced RIA in routine diagnostic laboratories. The full principle and limitations of the older method are on the radioimmunoassay page.

Against ELISA, the gain is different. ELISA produces a color measured by absorbance, which works well but has a narrower measuring range and generally lower sensitivity than light-based detection. CLIA's light signal can be detected at very low analyte concentrations and across several orders of magnitude, which is why modern automated serology platforms moved from colorimetric ELISA readouts toward chemiluminescent ones.

How the light is produced: the detection chemistry

The defining step is how the label generates light. Two broad designs are in common use.

1. In a direct chemiluminescent label design, the label itself (for example, an acridinium ester) is attached to the antibody. When a trigger reagent is added, the label undergoes a chemical reaction and emits a flash of light directly. The signal is read immediately.
2. In an enzyme-triggered design, an enzyme label (for example, alkaline phosphatase or horseradish peroxidase) acts on a chemiluminescent substrate to produce light. This is the same enzyme-label idea used in ELISA, but the substrate produces light instead of color. When the enzyme is the same as in ELISA but the readout is light, the method is sometimes called a chemiluminescent enzyme immunoassay.

A related variant, electrochemiluminescence immunoassay (ECLIA), generates light electrically at an electrode surface from a ruthenium label. It is widely used on large automated analyzers and follows the same interpretive logic as CLIA.

In every case, the sequence is the same: bind, wash away the unbound label, add the trigger, and measure the emitted light in relative light units (RLU).

CLIA versus ELISA

Both methods rely on the same antibody-antigen binding step; the difference is entirely in how the bound label is detected. That single change, from measuring color to measuring light, is what gives CLIA its higher sensitivity and wider measuring range, and it is why automated serology platforms have largely moved from colorimetric ELISA readouts to chemiluminescent ones.

Procedure and formats

CLIA can be run in the same formats as other immunoassays, and the format determines how the RLU relates to the analyte.

1. In a sandwich (two-site) format, used for larger antigens, the analyte is captured between a solid-phase antibody and a labeled antibody. More analyte means more label retained, so more light. The signal is directly proportional to the analyte concentration.
2. In a competitive format, used for small analytes, labeled and unlabeled analyte compete for a limited amount of antibody. More analyte in the sample means less labeled analyte bound, so less light. The signal is inversely proportional to the analyte concentration. This inversion is a common source of misreading and is addressed in the interpretation section.

On automated analyzers, magnetic microparticles usually serve as the solid phase, which speeds up the binding and washing steps and is part of why CLIA platforms are fast and hands-off.

Interpretation

From RLU to a result. The luminometer reports relative light units. RLU on its own is not a result; it is converted to a concentration against a calibration curve, or, for qualitative tests, compared to a cutoff.

The cutoff index (S/CO). Many qualitative CLIA tests report a signal-to-cutoff ratio, often written S/CO or COI (cutoff index). The instrument divides the sample's signal by the assay's cutoff value. An S/CO at or above 1.0 is reactive (positive); below 1.0 is non-reactive (negative). Values close to 1.0 fall in a grey zone that many assays flag for repeat or confirmatory testing. Reading the S/CO, not the raw RLU, is what a student needs to do at the bench.

Direction of the signal depends on the format. In a sandwich assay, high light means high analyte. In a competitive assay, high light means low analyte. Reading a competitive result as if it were a sandwich result inverts the answer. Always know which format the assay uses before interpreting the number.

High-dose hook effect. At very high analyte concentrations, a sandwich assay can paradoxically give a falsely low signal, because excess analyte saturates both the capture and the labeled antibody separately and prevents the sandwich from forming. This is the hook effect, and it is the CLIA counterpart of the prozone problem in agglutination and nephelometry. If a result looks implausibly low for a patient who is clearly positive on other grounds, dilution and retest is the check.

Reactive does not mean disease. As with any serological screen, a reactive CLIA result reflects the presence of the target antigen or antibody, not a final diagnosis. Reactive screening results are confirmed according to the relevant testing algorithm before they are reported as positive.

Limitations

CLIA requires a dedicated luminometer or automated analyzer, so it is more capital-intensive than a basic ELISA reader. The reagents and closed-system cartridges are often proprietary to the analyzer, which raises running cost and ties a lab to a platform.

Like all immunoassays, it is subject to interference from heterophile antibodies, biotin (in some designs), and sample handling errors, and to the hook effect at extreme concentrations. It reports the presence of an analyte, not a clinical diagnosis, so screening-positive results still need confirmation.

How to remember

Anchor CLIA on the signal, because the signal is the whole difference from its two neighbors:

• RIA emits radiation, ELISA emits color, CLIA emits light. Same binding idea, three different signals. CLIA keeps RIA's sensitivity without the radioactivity, and beats ELISA's range because light beats color for detection.
• Read the S/CO, not the RLU. RLU is raw light; S/CO is the answer. At or above 1.0 is reactive.
• Format flips the direction. Sandwich: more light, more analyte. Competitive: more light, less analyte.

Key exam facts

Where students get confused

"CLIA and ELISA are basically the same test." They share the antibody-antigen binding step and can use the same enzyme labels, but the readout is different: ELISA measures color by absorbance, CLIA measures light by luminometer. That difference is why CLIA is more sensitive and has a wider measuring range, and it is the reason to build a separate page rather than fold CLIA into ELISA.

"A higher RLU always means more of the analyte." Only in a sandwich format. In a competitive format, higher light means less analyte. The format decides the direction, so identify it before reading the number.

"The raw RLU is the result." It is not. For qualitative tests the result is the signal-to-cutoff ratio (S/CO), and for quantitative tests it is the concentration read off the calibration curve. RLU is the raw light signal before that conversion.

"A very low signal rules out disease." Not at extreme concentrations. The high-dose hook effect can drive a sandwich assay's signal falsely low when analyte is very high. If the low result does not fit the clinical picture, dilute and retest.

"CLIA is a confirmatory test." It is usually a screening or quantitative assay. A reactive screen is confirmed per the testing algorithm before being reported as positive.

References

1. Tille PM. Bailey & Scott's Diagnostic Microbiology. 15th ed. St. Louis: Elsevier; 2022.
2. Procop GW, et al. Koneman's Color Atlas and Textbook of Diagnostic Microbiology. 7th ed. Philadelphia: Wolters Kluwer; 2017.
3. Leber AL, editor. Clinical Microbiology Procedures Handbook. 4th ed. Washington, DC: ASM Press; 2016. doi:10.1128/9781683670438.CMPH